Sign inJoin waitlistJoin the waitlist

RR

Raajit Rampal

Director, Center for Hematologic Malignancies · New York Presbyterian Hospital

Credentials: · · · · · · ·

History

Myeloproliferative Neoplasms Program · New York Presbyterian Hospital
Present

Weill Cornell Medical College
2013–2014
Hematology and Medical Oncology
Memorial Sloan Kettering Cancer Center
2010–2013
Internal Medicine
University of Chicago Medical Center
2007–2010
Renaissance School of Medicine at Stony Brook University
2003–2007
B.S. University of Rochester, 1999
1995–1999

Research

Single-cell mutation analysis of clonal evolution in myeloid malignancies
Nature · 2020 · 415 citations
Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis
Blood · 2014 · First of 17 authors · 356 citations
Efficacy of MEK inhibition in patients with histiocytic neoplasms
Nature · 2019 · 341 citations

John Mascarenhas
47 papers
Ross Levine
46 papers
Omar Abdel-Wahab
31 papers · 1 as a fellow
Ruben Mesa
26 papers
MT
Martin Tallman
24 papers
Ronald Hoffman
24 papers
Prithviraj Bose
19 papers
SV
Srdan Verstovsek
16 papers
Aaron Gerds
15 papers
Eli Diamond
15 papers
GH
Gabriela Hobbs
15 papers · 2 as a fellow
Marina Kremyanskaya
15 papers

Grants

Myeloproliferative Neoplasms-Research Consortium
National Cancer Institute · P01
Project lead · $5.3M · Icahn School of Medicine at Mount Sinai
2006–2028
Evaluation of Genetic and Epigenetic Determinants of Response in Patients with Accelerated and Blast Phase Myeloproliferative Neoplasm (MPNs)
National Cancer Institute · R21
Contact PI · $444.6K · Sloan-Kettering Inst Can Research
2026–2028
Investigation of the Impact of Pegylated Interferon on Clonal Trajectory and Inflammatory Cytokine Production in MPN Patients
National Cancer Institute · R21
Contact PI · $451K · Sloan-Kettering Inst Can Research
2021–2024
Genomic Profiling and Development of Murine Models of Transformation of MPNs
National Cancer Institute · K08
Contact PI · $891K · Sloan-Kettering Inst Can Research
2014–2020

Clinical trials

MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
Principal investigator · Recruiting
MPN Research Foundation
2025–2035
A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
Principal investigator · Recruiting · Phase 1, Phase 2
Memorial Sloan Kettering Cancer Center
2025–2028
A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis
Principal investigator · Recruiting · Phase 1
Memorial Sloan Kettering Cancer Center
2023–2027
A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis
Principal investigator · Active not recruiting · Phase 2
Memorial Sloan Kettering Cancer Center
2017–2027